[Plasmacytoïd dendritic cells acute leukemia: a case report].

Area of Science:

• Hematology
• Oncology
• Immunophenotyping

Background:

• Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy.
• Diagnosis can be challenging due to non-specific clinical and laboratory findings.

Observation:

• The case involved a patient hospitalized for BPDCN treatment.
• Skin lesions are present in 83% of patients at diagnosis.
• Cytology is not characteristic, and no specific cytogenetic abnormality exists for BPDCN.

Findings:

• Definitive diagnosis relies on identifying a blastic population with a CD4+ CD56+ immunophenotype.
• The karyotype typically shows at least three cytogenetic abnormalities.
• BPDCN is chemosensitive, but has a high relapse rate and a median survival of 16 months.

Implications:

• Accurate immunophenotypic analysis is crucial for BPDCN diagnosis.
• The high relapse rate underscores the need for improved therapeutic strategies.
• Understanding BPDCN's clinical course is vital for patient management and prognosis.